IL158589A0 - Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes - Google Patents
Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetesInfo
- Publication number
- IL158589A0 IL158589A0 IL15858902A IL15858902A IL158589A0 IL 158589 A0 IL158589 A0 IL 158589A0 IL 15858902 A IL15858902 A IL 15858902A IL 15858902 A IL15858902 A IL 15858902A IL 158589 A0 IL158589 A0 IL 158589A0
- Authority
- IL
- Israel
- Prior art keywords
- ppar
- diabetes
- alpha
- treatment
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111745 | 2001-05-15 | ||
| PCT/EP2002/004962 WO2002092084A1 (en) | 2001-05-15 | 2002-05-06 | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158589A0 true IL158589A0 (en) | 2004-05-12 |
Family
ID=8177436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15858902A IL158589A0 (en) | 2001-05-15 | 2002-05-06 | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
| IL158589A IL158589A (en) | 2001-05-15 | 2003-10-23 | Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL158589A IL158589A (en) | 2001-05-15 | 2003-10-23 | Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6642389B2 (es) |
| EP (1) | EP1392295B1 (es) |
| JP (2) | JP4330883B2 (es) |
| KR (1) | KR100654516B1 (es) |
| CN (1) | CN100356917C (es) |
| AR (1) | AR035892A1 (es) |
| AT (1) | ATE327753T1 (es) |
| AU (1) | AU2002342244B2 (es) |
| BG (1) | BG66316B1 (es) |
| BR (1) | BRPI0209821B1 (es) |
| CA (1) | CA2445145C (es) |
| CY (1) | CY1105160T1 (es) |
| CZ (1) | CZ20033037A3 (es) |
| DE (1) | DE60211891T2 (es) |
| DK (1) | DK1392295T3 (es) |
| EC (1) | ECSP034848A (es) |
| EG (1) | EG25755A (es) |
| ES (1) | ES2264482T3 (es) |
| GT (1) | GT200200085A (es) |
| HK (1) | HK1067534A1 (es) |
| HR (1) | HRP20030889B1 (es) |
| HU (1) | HU230224B1 (es) |
| IL (2) | IL158589A0 (es) |
| JO (1) | JO2282B1 (es) |
| MA (1) | MA27025A1 (es) |
| ME (1) | ME01310B (es) |
| MX (1) | MXPA03010435A (es) |
| MY (1) | MY136761A (es) |
| NO (1) | NO333833B1 (es) |
| NZ (1) | NZ529033A (es) |
| PA (1) | PA8544901A1 (es) |
| PE (1) | PE20021152A1 (es) |
| PL (1) | PL208074B1 (es) |
| PT (1) | PT1392295E (es) |
| RU (1) | RU2278859C2 (es) |
| SI (1) | SI1392295T1 (es) |
| SK (1) | SK287842B6 (es) |
| WO (1) | WO2002092084A1 (es) |
| ZA (1) | ZA200308538B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1295875A4 (en) * | 2000-05-26 | 2004-05-06 | Nippon Shinyaku Co Ltd | HETEROCYCLIC COMPOUNDS |
| CZ20033037A3 (cs) * | 2001-05-15 | 2004-06-16 | F. Hoffmann-La Roche Ag | Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| WO2003013571A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| ATE415160T1 (de) | 2002-02-25 | 2008-12-15 | Lilly Co Eli | Modulatoren von peroxisome proliferator- aktivierten rezeptoren |
| RU2296754C2 (ru) * | 2002-08-30 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ |
| TWI343915B (en) * | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
| US20060142277A1 (en) * | 2002-11-15 | 2006-06-29 | Cadila Healthcare Limited | Substituted aralkyl derivatives |
| KR100713266B1 (ko) * | 2002-11-25 | 2007-05-04 | 에프. 호프만-라 로슈 아게 | 인돌릴 유도체 |
| US7268157B2 (en) * | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
| FR2849849B1 (fr) * | 2003-01-13 | 2006-08-04 | Merck Sante Sas | Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7262303B2 (en) | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| BRPI0416284A (pt) * | 2003-11-05 | 2007-01-23 | Hoffmann La Roche | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e sua utilização |
| MXPA06004641A (es) * | 2003-11-05 | 2006-06-27 | Hoffmann La Roche | Derivados de fenilo como agonistas para. |
| WO2005056536A1 (en) * | 2003-12-10 | 2005-06-23 | Ranbaxy Laboratories Limited | Antidiabetic agents which exhibit activity against ppar |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| AU2005238176B2 (en) | 2004-05-03 | 2008-11-27 | F. Hoffmann-La Roche Ag | Indolyl derivatives as liver-X-receptor modulators |
| CN100436430C (zh) * | 2004-05-24 | 2008-11-26 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物 |
| CN100344618C (zh) * | 2004-05-24 | 2007-10-24 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物 |
| WO2006108491A1 (en) * | 2005-04-11 | 2006-10-19 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Improved process for preparing oxazole nitriles |
| US20060241073A1 (en) * | 2005-04-20 | 2006-10-26 | Wanders Ronaldus J A | Means and methods for counteracting fatty acid accumulation |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| KR100847780B1 (ko) * | 2006-10-26 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제 |
| US20100063041A1 (en) * | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| PT2100604E (pt) * | 2008-03-10 | 2012-07-24 | Nestec Sa | Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas |
| US20110124661A1 (en) * | 2008-05-15 | 2011-05-26 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
| CA2747332C (en) | 2008-12-23 | 2015-01-27 | F. Hoffmann-La Roche Ag | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
| PL2389166T3 (pl) | 2009-01-23 | 2013-04-30 | Hoffmann La Roche | Kompozycja farmaceutyczna zawierająca aleglitazar |
| CN101805337B (zh) * | 2009-02-13 | 2012-05-23 | 天津药物研究院 | 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途 |
| US8450496B2 (en) * | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
| PL2585452T3 (pl) | 2009-12-07 | 2016-03-31 | Hoffmann La Roche | Sposób wytwarzania pochodnych kwasu propionowego |
| CN102351852B (zh) * | 2011-08-23 | 2014-06-18 | 上海交通大学 | 苯并呋喃类化合物及其制备方法、用途 |
| WO2013181384A1 (en) | 2012-05-31 | 2013-12-05 | Ratiopharm Gmbh | Solid state forms of aleglitazar sodium |
| KR20150054829A (ko) * | 2012-09-12 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | (S)-2-메톡시-3-｛4-[2-(5-메틸-2-페닐-옥사졸-4-일)-에톡시]-벤조[b]티오펜-7-일｝-프로피온산 및 이의 염의 고체 형태 |
| CN109588042A (zh) | 2015-11-18 | 2019-04-05 | 豪夫迈·罗氏有限公司 | 用于治疗糖尿病肾病的阿格列扎 |
| WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| WO2020156683A1 (en) | 2019-02-01 | 2020-08-06 | F. Hoffmann-La Roche Ag | Aleglitazar for use in the treatment or prevention of major adverse cardiac events |
| WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
| CN116848095B (zh) * | 2021-08-13 | 2024-05-24 | 礼邦生物医药(江苏)有限公司 | 氘代化合物 |
| WO2024100051A1 (en) | 2022-11-08 | 2024-05-16 | Genfit | Ppar-alpha/gamma agonist for use in the treatment of liver failure |
| CN118480034A (zh) * | 2023-02-13 | 2024-08-13 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011326A (en) | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| PL174610B1 (pl) | 1992-07-03 | 1998-08-31 | Smithkline Beecham Plc | Nowe związki heterocykliczne |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| IL129999A (en) | 1996-12-10 | 2004-06-20 | Bristol Myers Squibb Co | Melatonergic agents which are benzodioxole, benzopuran, dihydrobenzopuran and benzodioxane |
| DE19711616A1 (de) * | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
| US6121397A (en) | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
| HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| DE69815008T2 (de) | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel |
| WO1999008501A2 (en) | 1998-04-23 | 1999-02-25 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DK1078923T3 (da) | 1999-08-02 | 2006-07-10 | Hoffmann La Roche | Fremgangsmåde til fremstilling af benzothiophenderivater |
| DE60128239T2 (de) * | 2000-08-23 | 2008-01-10 | Eli Lilly And Co., Indianapolis | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten |
| CZ20033037A3 (cs) * | 2001-05-15 | 2004-06-16 | F. Hoffmann-La Roche Ag | Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu |
-
2002
- 2002-05-06 CZ CZ20033037A patent/CZ20033037A3/cs unknown
- 2002-05-06 CN CNB028100964A patent/CN100356917C/zh not_active Expired - Fee Related
- 2002-05-06 NZ NZ529033A patent/NZ529033A/en not_active IP Right Cessation
- 2002-05-06 ES ES02742955T patent/ES2264482T3/es not_active Expired - Lifetime
- 2002-05-06 AT AT02742955T patent/ATE327753T1/de active
- 2002-05-06 KR KR1020037014816A patent/KR100654516B1/ko active IP Right Grant
- 2002-05-06 AU AU2002342244A patent/AU2002342244B2/en not_active Ceased
- 2002-05-06 CA CA002445145A patent/CA2445145C/en not_active Expired - Fee Related
- 2002-05-06 ME MEP-2008-775A patent/ME01310B/me unknown
- 2002-05-06 SK SK1385-2003A patent/SK287842B6/sk not_active IP Right Cessation
- 2002-05-06 IL IL15858902A patent/IL158589A0/xx unknown
- 2002-05-06 MX MXPA03010435A patent/MXPA03010435A/es active IP Right Grant
- 2002-05-06 DE DE60211891T patent/DE60211891T2/de not_active Expired - Lifetime
- 2002-05-06 BR BRPI0209821A patent/BRPI0209821B1/pt not_active IP Right Cessation
- 2002-05-06 PL PL367087A patent/PL208074B1/pl unknown
- 2002-05-06 WO PCT/EP2002/004962 patent/WO2002092084A1/en active IP Right Grant
- 2002-05-06 HU HU0400992A patent/HU230224B1/hu not_active IP Right Cessation
- 2002-05-06 PT PT02742955T patent/PT1392295E/pt unknown
- 2002-05-06 RU RU2003134150/04A patent/RU2278859C2/ru not_active IP Right Cessation
- 2002-05-06 SI SI200230340T patent/SI1392295T1/sl unknown
- 2002-05-06 DK DK02742955T patent/DK1392295T3/da active
- 2002-05-06 JP JP2002589001A patent/JP4330883B2/ja not_active Expired - Fee Related
- 2002-05-06 EP EP02742955A patent/EP1392295B1/en not_active Expired - Lifetime
- 2002-05-09 US US10/142,567 patent/US6642389B2/en not_active Expired - Lifetime
- 2002-05-13 JO JO200242A patent/JO2282B1/en active
- 2002-05-13 MY MYPI20021726A patent/MY136761A/en unknown
- 2002-05-13 AR ARP020101739A patent/AR035892A1/es active IP Right Grant
- 2002-05-14 GT GT200200085A patent/GT200200085A/es unknown
- 2002-05-14 EG EG2002050495A patent/EG25755A/xx active
- 2002-05-14 PE PE2002000399A patent/PE20021152A1/es active IP Right Grant
- 2002-05-14 PA PA20028544901A patent/PA8544901A1/es unknown
-
2003
- 2003-10-23 IL IL158589A patent/IL158589A/en unknown
- 2003-10-31 ZA ZA2003/08538A patent/ZA200308538B/en unknown
- 2003-11-04 HR HR20030889A patent/HRP20030889B1/xx not_active IP Right Cessation
- 2003-11-13 EC EC2003004848A patent/ECSP034848A/es unknown
- 2003-11-14 NO NO20035086A patent/NO333833B1/no not_active IP Right Cessation
- 2003-11-14 MA MA27399A patent/MA27025A1/fr unknown
- 2003-11-14 BG BG108362A patent/BG66316B1/bg unknown
-
2004
- 2004-12-07 HK HK04109665A patent/HK1067534A1/xx not_active IP Right Cessation
-
2006
- 2006-08-22 CY CY20061101162T patent/CY1105160T1/el unknown
-
2009
- 2009-02-10 JP JP2009028181A patent/JP2009138011A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL158589A0 (en) | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes | |
| HUP0401647A3 (en) | Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds | |
| IL172170A0 (en) | Propionic acid derivatives useful in the treatment of lipid disorders | |
| IL178151A0 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes | |
| HK1087103A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| HK1073441A1 (en) | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes | |
| WO2000045799A3 (de) | Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe | |
| AU2003279442A8 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
| IL169489A0 (en) | Use of derivatives of succinate esters for the treatment of dementia | |
| JO3106B1 (ar) | مستحضر صلب يشمل بيوجليتازون وجليمبيريد وإستر حمض دهني لعديد أوكسي إيثيلين سوربيتان | |
| HUP0302306A3 (en) | Propionic acid derivatives with ppar-alpha activating properties | |
| IL143594A0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | |
| SI1539746T1 (sl) | Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa | |
| EP1660490A4 (en) | CHROMANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | |
| PL375074A1 (en) | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | |
| PL375080A1 (en) | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | |
| YU89903A (sh) | Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa | |
| PL378059A1 (pl) | Optycznie czynne pochodne bisoksazoliny, sposób ich wytwarzania i zastosowania | |
| AU2003297807A1 (en) | Use of n-chlorotaurine for treatment of oozing tissue deficiencies | |
| AU2003215677A1 (en) | N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases | |
| GB9922709D0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | |
| EP1539175A4 (en) | SUBSTITUTED INDOLALCANIC ACID DERIVATIVES AND FORMULATIONS CONTAINING THEREOF FOR USE IN THE TREATMENT OF DIABETIC COMPLICATIONS | |
| SI1517883T1 (sl) | Orto-substituirani derivati benzojske kisline za zdravljenje insulinske rezistence | |
| SI1517679T1 (sl) | Orto-substituirani derivati benzojske kisline za zdravljenje insulinske rezistence | |
| AU2003237007A1 (en) | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |